Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.
Press releases published on September 2, 2025
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
GlobeNewswire
·
September 2, 2025
Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with potential for more than $400 million …
Electric Hydrogen Strengthens European Operations with Appointment of General Manager
GlobeNewswire
·
September 2, 2025
• Established hydrogen industry professional Bruno Forget to lead European and MENA business • Evidence of Electric Hydrogen's continued commitment to meet demand for large-scale and low-cost renewable hydrogen systems in Europe LONDON, Sept. 02, 2025 ( …
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy
GlobeNewswire
·
September 2, 2025
Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November 2025 The trial builds on Phase 2a double-blind, …
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
GlobeNewswire
·
September 2, 2025
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior efficacy, durability and safety; …
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
GlobeNewswire
·
September 2, 2025
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company pioneering a transformative approach …
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
GlobeNewswire
·
September 2, 2025
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard is a …